Day One Biopharmaceuticals, Inc.
DAWN evidence brief
What we can confirm
- BioSniper Score:
- 7.3 / 10
- Market Cap:
- $2.22B
- Lead Asset:
- emi-le (Phase 1)
What it means
What to watch
Prepared research question
What matters most for DAWN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$2.22B
Cash Runway
—
Lead Asset
emi-le (Phase 1)
Next Catalyst
—
Tracking 2 pipeline candidates for Day One Biopharmaceuticals, Inc..
Run Day One Biopharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Day One Biopharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
207
Total value held
$1.74B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 7,044,487 | $151.0M |
| fil ltd | 4,131,907 | $88.6M |
| kryger capital llc | 3,896,485 | $83.5M |
| deerfield management company, l.p. | 3,723,131 | $79.8M |
| vanguard capital management llc | 3,357,684 | $72.0M |
| jpmorgan chase & co | 3,134,753 | $67.1M |
| state street corp | 2,869,876 | $61.5M |
| balyasny asset management l.p. | 2,625,235 | $56.3M |
| aqr arbitrage llc | 2,462,154 | $52.8M |
| ubs group ag | 2,305,123 | $49.4M |
Showing top 10 of 207 institutional holders of Day One Biopharmaceuticals, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 24, 2026- % of float
- 10.3%
- Days to cover
- 0.9
- Shares short
- 7,236,832
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
DAWN short interestGovernance
Frequently asked questions
What is Day One Biopharmaceuticals, Inc.'s lead drug candidate?
Day One Biopharmaceuticals, Inc.'s most advanced tracked candidate is emi-le (Phase 1) for Adenoid cystic carcinoma (ACC) and other adult and pediatric cancers expressing B7-H4.
Who is the CEO of Day One Biopharmaceuticals, Inc.?
Dr. Jeremy Bender M.B.A., Ph.D. is the chief executive officer of Day One Biopharmaceuticals, Inc. (DAWN).
Where is Day One Biopharmaceuticals, Inc. headquartered?
Day One Biopharmaceuticals, Inc. (DAWN) is headquartered in Brisbane, CA, United States.
What therapeutic areas does Day One Biopharmaceuticals, Inc. focus on?
Day One Biopharmaceuticals, Inc. develops therapies across Oncology, Infectious Disease, Endocrinology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.